Regulation, Reimbursement Notes From Turkey
This article was originally published in PharmAsia News
Executive Summary
A PharmAsia News update on Turkish biomedical regulatory policies, including plans to increase local manufacture of cancer drugs by 2018, a key industry appointment, an adverse reporting initiative and 16 generic drugs added to Turkey’s reimbursement list.